A Phase II Open-Label Multicenter Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as neoadjuvant and adjuvant therapy in Patients with Stage IB II or IIIA resectable and untreated non-small cell lung cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have pathologically documented non-small cell lung cancer; Stage IB, II, or IIIA

     

    2.  Patients must be candidates for definitive surgical resection of their cancer.

     

    3.  There must be adequate tissue from biopsies before and after treatment to evaluate markers of response to treatment.


You may not be eligible for this study if the following are true:

  • 1.  Patients with active hepatitis B (chronic or acute) or active hepatitis C virus infection

     

    2.  Patients receiving any live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study or within 5 months after the last dose of atezolizumab

     

    3.  Patients with any active autoimmune disease or requiring systemic steroids.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.